AUTHORS
Nesrine Khachroumi, N/A, Thierry Lobbedez, MD2, Aude Servais, MD, PHD3, François Provot, MD4, Steven Grange, MD5, Moglie Le Quintrec, MD, PHD6, Olivia Boyer, MD, PHD7, Thérésa Kwon, MD8, Elie Azoulay, MD, PHD9, Pierre Perez, MD10, Carole Philipponnet, MD11, Claire Cartery, MD12, Jean-Francois Augusto, MD, PHD13, Loic LIEVRE, MD14, Alexandre Hertig, MD, PHD15, Yahsou Delmas, MD16, Gabriel Choukroun, MD, PHD17, Christelle Barbet, MD18, Jean-Michel Halimi, MD, PHD19, Stanislas Faguer, MD, PHD20, Sophie OHLMANN, MD, PHD21, Raïda Bouzid, MD, PHD22, Veronique Fremeaux-Bacchi, MD23, Laurent Mesnard, MD, PHD24, Paul Coppo, MD25, Valerie Chatelet, MD, PHD26
AFFILIATIONS
1 ANTICIPE U1086 INSERM-UCN, Caen, Normandie, France
2 ANTICIPE U1086 INSERM-UCN, Caen, Normandie, France, Centre Hospitalier Universitaire de Caen, Caen, Normandie, France
3 Department of Kidney and Metabolic Diseases, Transplantation and Clinical Immunology, Necker Hospital, APHP, Paris, Ile de France, France
4 Department of Adult Nephrology Hôpital Albert Calmette, Lille, Hauts de France, France
5 Department of Nephrology, CIC-CRB 1404 (D.B., S.G.),, Rouen, Normandie, France
6 Centre Hospitalier Universitaire de Lapeyronie, Département de Néphrologie Dialyse et Transplantation Rénale, Montpellier, France
7 Imagine Institute, INSERM U1163,Paris Cité University, Paris, Ile de France, France
8 Service de Néphrologie Pédiatrique, Hôpital Robert-Debré, AP-HP.Nord, Université Paris Cité, Paris, Ile de France, France
9 Médecine Intensive Réanimation, Hôpital Saint Louis, APHP, Paris, Ile de France, France
10 Service de Médecine Intensive Réanimation, Hôpital Brabois,, Nancy, France
11 Service de Néphrologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
12 Service de Néphrologie, CH de Valenciennes, Valenciennes, France
13 Service de Néphrologie-Dialyse-Transplantation, CHU d’Angers, Angers, France
14 Service de Néphrologie, Hôpital Maison Blanche, Reims, Reims, France
15 Service de Néphrologie, Hôpital Foch-Suresnes, Paris, Ile de France, France
16 Service de Néphrologie, CHU Bordeaux, Bordeaux, France
17 laboratoire MP3CV, UPJV, Amiens, Picardie, France
18 Service de Néphrologie-Immunologie Clinique, CHRU de Tours,, Tours, France
19 Service de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, CHRU Tours, Tours, France
20 Department of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, INSERM U1297, Toulouse, France
21 Service de Néphrologie, CHU de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
22 INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Paris, France, Paris, Ile de France, France
23 Department of Immunology, AP-HP, Georges Pompidou European Hospital, Paris, France
24 Service de Néphrologie, Hôpital Tenon, APHP.SU, Paris, Paris, France
25 French Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital Saint Antoine, AP-HP.SU, Paris, France, Paris, France, INSERM Unité Mixte de Recherche (UMRS) 1138, Paris, Ile de France, France
26 ANTICIPE U1086 INSERM-UCN, Caen, Normandie, France, Centre Hospitalier Universitaire de Caen, Caen, Normandie, France
ABSTRACT
Background
Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated disease that carries a high risk of acute kidney injury and life-threatening complications. Despite major therapeutic advances, the clinical course of aHUS remains highly heterogeneous. In this context, social factors are increasingly recognized as key contributors to disparities in chronic diseases, including kidney diseases. In France, the National Plan for Rare Diseases, initiated in 2004 aims to ensure equitable access to diagnosis, treatment, and specialized care through structured networks of reference centers. However, inequalities in healthcare access and outcomes may persist. In aHUS, the influence of social deprivation on outcomes in this population remains poorly understood. Here, we used the European Deprivation Index (EDI), an ecological index validated in nephrology, provides a robust measure of socioeconomic deprivation at a small-area geographic unit level, capturing both objective and subjective dimensions of poverty. We aimed to assess the association between social deprivation and adverse clinical outcomes in patients with aHUS.
Methods
We analyzed data from 248 patients diagnosed with aHUS between 2000 and 2024 from the French National Reference Center for Thrombotic Microangiopathies (CNR-MAT). Social deprivation was measured using the EDI, a composite ecological measure of social deprivation. Each patient was assigned to the smallest French geographical unit for which aggregated socioeconomic data are available, based on their address; an EDI score was subsequently assigned. The EDI corresponds to the weighted sum of 10 binary variables reflecting socioeconomic level. It combines individual-level data from the European Union Statistics on Income and Living Conditions (EU-SILC) survey with national census data, enabling comparisons across time and between European countries. The EDI is calculated at the the smallest French geographical unit level and categorized into five quintiles based on the national distribution, ranging from quintile 1 (least deprived) to quintile 5 (most deprived). Here, social deprivation was dichotomized to compare patients residing in the most deprived areas (quintile 5) with those living in less deprived areas (quintiles 1-4). Logistic regression models assessed the association between social deprivation and major adverse kidney events (MAKE), a renal composite outcome (kidney transplantation or hemodialysis [HD]), and disease relapse. Mediation analyses evaluated whether eculizumab use, platelet count, or plasma exchange during the acute episode mediated the association between social deprivation and MAKE.
Results
238 patients were included in the analysis. A past relevant medical history was reported in 70% of patients, with comparable proportions across deprivation strata. 104 (43.7%) belonged to the most deprived EDI quintile (Q5). MAKE occurred in 52 patients (52%) in the highest deprivation quintile (Q5), compared with 51 patients (40%) in the lower deprivation quintiles (p=0.08). A similar gradient was observed for the renal composite outcome, which occurred in 47 patients (48%) in Q5 versus 46 patients (36%) in the less deprived group (p=0.08). Relapse during follow-up was also more prevalent among the most deprived patients, affecting 31 individuals (31%) compared with 28 individuals (22%) (p=0.13) in the lower deprivation group. Patients in Q5 had higher odds of experiencing MAKE (odds ratio [OR] 2.17, 95% CI 1.21-3.90) and the renal composite outcome (OR 2.02, 95% CI 1.10-3.62). No significant association was observed with disease relapse (OR 1.47, 95% CI 0.79-2.74). Mediation analyses did not identify significant indirect effects of eculizumab use, platelet count, or plasma exchange; therefore, these variables did not appear to mediate the association between social deprivation and major adverse kidney events.
Conclusion
Social deprivation is common and associated with an increased risk of major adverse kidney events in patients with aHUS. This association was not explained by eculizumab use, platelet count, or plasma exchange during the acute phase, suggesting that the association between social deprivation and renal outcomes is not mediated by the severity of the disease at the acute phase or by the initial therapeutic strategies. Other, unmeasured pathways could be involved, including organizational and healthcare system-related factors that remain to be explored.
DISCLOSURES
Paul Coppo, MD: Sanofi - Honoraria; Takeda - Honoraria; Alexion - Honoraria; Sanofi - Research Funding; Takeda - Research Funding; Alexion - Research Funding